Last updated: February 26, 2026
What is the drug associated with NDC 60505-6249?
The National Drug Code (NDC) 60505-6249 corresponds to a specific pharmaceutical product. Based on available databases, this code is assigned to Eptinezumab, marketed under the brand name Vyepti. Eptinezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for preventive treatment of migraine in adults.
What is the market size for Eptinezumab?
Total Addressable Market (TAM)
- The global migraine market was valued at approximately USD 4.8 billion in 2022.
- The North American region accounts for around 60-65% of this market.
- The prevalence of migraine in adults is estimated at 12% globally, with higher incidence among females.
Competitive landscape
- Major competitors include erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti).
- Eptinezumab's unique delivery method is intravenous infusion every 3 months, differentiating it from subcutaneous options.
Current market penetration
- Eptinezumab's market share is estimated at approximately 8-10% within the CGRP antibody segment.
- Sales for Vyepti reached about USD 230 million in 2022, with potential for growth as market penetration expands.
What are the price points and reimbursement policies?
List Price
- The wholesale acquisition cost (WAC) for Vyepti is approximately USD 980 per vial.
- Patients typically receive a 100 mg dose per infusion, with infusion intervals every three months.
Reimbursement Considerations
- Medicare and private insurers generally cover CGRP therapies.
- Reimbursement rates vary; commercial insurers often negotiate discounts, reducing the net price.
Cost comparison with competitors
| Drug |
Price per Dose |
Administration |
Dosing Schedule |
Annual Cost (assuming 4 doses) |
| Vyepti (Eptinezumab) |
USD 980 |
Intravenous infusion |
Quarterly |
USD 3,920 |
| Aimovig (Erenumab) |
USD 575 |
Subcutaneous injection |
Monthly |
USD 6,900 |
| Ajovy (Fremanezumab) |
USD 575 |
Subcutaneous injection |
Monthly or quarterly |
USD 2,300 – 6,900 |
| Emgality (Galcanezumab) |
USD 575 |
Subcutaneous injection |
Monthly |
USD 6,900 |
What are the future price and market projections?
Market growth forecasts
- The CGRP inhibitor market is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030.
- Increased adoption is driven by expanding indication approvals and insurance coverage.
Price evolution predictions
- As biosimilars and competitors enter the market, list prices for biologics like Vyepti may decline by 15-25% over 3-5 years.
- Payer negotiations and formulary placements could further reduce net prices by 20-30%.
Impact of regulatory and policy developments
- Potential for price caps or negotiated pricing under Medicare Part D.
- Outcomes of international reference pricing may influence U.S. list prices.
Key factors influencing market and pricing
- Market penetration: Growing acceptance among neurologists and patients increases sales.
- Reimbursement and coverage policies: Broader insurer inclusion facilitates access.
- Pricing strategies: Manufacturer discounts and patient assistance programs impact net prices.
- Competitive launches: Biosimilars or new entrants could pressure prices downward.
Key Takeaways
- Eptinezumab (Vyepti) competes within a USD 4.8 billion global migraine market, capturing a growing segment.
- Current list price is approximately USD 980 per infusion, with annual costs near USD 3,920.
- Market growth, insurance coverage, and competitive pressures are expected to influence future pricing.
- Price erosion from biosimilars and formulary negotiations could decrease net prices by up to 30% over the next five years.
- Expansion into new indications or combination therapies could influence sales volume more significantly than price adjustments.
FAQs
1. How does Eptinezumab's infusion schedule affect market adoption?
The intravenous infusion every three months may limit convenience compared to subcutaneous options, potentially impacting patient adherence but possibly appealing for certain clinical settings.
2. Are biosimilars expected for Eptinezumab?
Biosimilar development for monoclonal antibody therapies is ongoing, but no biosimilar for Vyepti has been approved as of 2023.
3. How do insurance policies impact access to Eptinezumab?
Reimbursement policies vary; coverage expands with accepted formulary status and clinical guidelines, influencing patient uptake and market share.
4. What are the drivers for price reductions?
Entry of biosimilars, increased competition, pricing pressures from payers, and market saturation are primary drivers.
5. What future factors could influence the market size?
New indications, combination treatments, and improved treatment algorithms could expand the patient population, impacting overall market size more than price changes.
References
[1] IQVIA. (2022). Pharmaceutical Market Estimates.
[2] FDA. (2019). Eptinezumab (Vyepti) Approval Letter.
[3] EvaluatePharma. (2022). World Preview: Outlook to 2027.
[4] CMS. (2023). Medicare Reimbursement Policies for Biologics.
[5] Statista. (2022). Global Migraine Market Revenue.
